Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas

Cancer Immunology, Immunotherapy

Volumn 65, Issue 7, 2016, Pages 771-778

  Beatty, Pamela L ^a   van der Geest, Rick ^a   Hashash, Jana G ^b   Kimura, Takashi ^c   Gutkin, Dmitriy ^a   Brand, Randall E ^b   Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cancer vaccines; CITIM 2015; Immunosurveillance; IPMN; MUC1; Pancreatic cancer

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATED GENE 3 PROTEIN; MUCIN 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN; T CELL IMMUNOGLOBULIN AND MUCIN CONTAINING PROTEIN 3 PROTEIN; UNCLASSIFIED DRUG; MUC1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER PATIENT; CANCER PREVENTION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOLOGICAL MEMORY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; LYMPHOCYTIC INFILTRATION; PANCREAS ADENOCARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ADENOCARCINOMA; BIOSYNTHESIS; BLOOD; COLLOID CARCINOMA; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; MALE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PRECANCER; PROCEDURES;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MONITORING, IMMUNOLOGIC; MUCIN-1; PANCREATIC NEOPLASMS; PRECANCEROUS CONDITIONS;

EID: 84964200075     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1838-1     Document Type: Article

References (36)

1. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465
2. Lipson EJ, Drake CG (2011) Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 17(22):6958–6962
3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454
4. Ledford H (2013) Immunotherapy’s cancer remit widens. Nature 497(7451):544
5. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174
6. Schmielau J, Finn OJ (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 61(12):4756–4760
7. Whiteside TL (2014) Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin Biol Ther 14(10):1411–1425
8. Woodford D, Johnson SD, De Costa AM, Young MR (2014) An inflammatory cytokine milieu is prominent in premalignant oral lesions, but subsides when lesions progress to squamous cell carcinoma. J Clin Cell Immunol 5(3):230. doi:10.4172/2155-9899.1000230
9. Shi C, Hruban RH (2012) Intraductal papillary mucinous neoplasm. Hum Pathol 43(1):1–16
10. Klibansky DA, Reid-Lombardo KM, Gordon SR, Gardner TB (2012) The clinical relevance of the increasing incidence of intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol 10(5):555–558
11. Tanaka M (2015) International consensus on the management of intraductal papillary mucinous neoplasm of the pancreas. Ann Transl Med 3(19):286
12. Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL (2007) Clinical implications and utility of field cancerization. Cancer Cell Int 7:2
13. Matthaei H, Norris AL, Tsiatis AC, Olino K, Hong SM, dal Molin M, Goggins MG, Canto M, Horton KM, Jackson KD, Capelli P, Zamboni G, Bortesi L, Furukawa T, Egawa S, Ishida M, Ottomo S, Unno M, Motoi F, Wolfgang CL, Edil BH, Cameron JL, Eshleman JR, Schulick RD, Maitra A, Hruban RH (2012) Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 255(2):326–333
14. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ (2004) MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 82:249–293
15. Kimura T, Finn OJ (2013) MUC1 immunotherapy is here to stay. Expert Opin Biol Ther 13(1):35–49
16. Barnd DL, Lan MS, Metzgar RS, Finn OJ (1989) Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86(18):7159–7163
17. Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, Bast RC Jr, Finn OJ (1991) Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 51(11):2908–2916
18. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ (1993) Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 151(7):3693–3703
19. Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y (2003) Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 103(1):97–100
20. Pinheiro SP, Hankinson SE, Tworoger SS, Rosner BA, McKolanis JR, Finn OJ, Cramer DW (2010) Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses’ Health Studies. Cancer Epidemiol Biomarkers Prev 19(6):1595–1601
21. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J (2000) Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18(3):574–583
22. Ajioka Y, Watanabe H, Jass JR (1997) MUC1 and MUC2 mucins in flat and polypoid colorectal adenomas. J Clin Pathol 50(5):417–421
23. Beatty PL, Plevy SE, Sepulveda AR, Finn OJ (2007) Cutting edge: transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer. J Immunol 179(2):735–739
24. Kadayakkara DK, Beatty PL, Turner MS, Janjic JM, Ahrens ET, Finn OJ (2010) Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis. Pancreas 39(4):510–515
25. Vlad AM, Diaconu I, Gantt KR (2006) MUC1 in endometriosis and ovarian cancer. Immunol Res 36(1–3):229–236
26. Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, Schoen RE, Finn OJ (2013) MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 6(1):18–26
27. Cramer DW, Titus-Ernstoff L, McKolanis JR, Welch WR, Vitonis AF, Berkowitz RS, Finn OJ (2005) Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 14(5):1125–1131
28. Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplancke B, Romero P, Rufer N, Speiser DE (2011) Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest 121(6):2350–2360
29. Ferris RL, Lu B, Kane LP (2014) Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J Immunol 193(4):1525–1530
30. + T cell dysfunction in melanoma patients. J Exp Med 207(10):2175–2186
31. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991–998
32. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360
33. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15(17):5323–5337
34. Pardoll D (2015) Cancer and the Immune System: Basic Concepts and Targets for Intervention. Semin Oncol 42(4):523–538
35. Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetschel M, Finn OJ (2005) Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 54(3):254–264
36. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DA (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72(4):917–927